Spinal cord injury.example of clonus part 2

By: Ponz59

See the original post:
Spinal cord injury.example of clonus part 2 - Video

Recommendation and review posted by sam

Living With Arachnoiditis: Coping with Obliterated Cervical Lordosis
I am NOT a doctor. I am a very experienced patient sharing methods that I have tried and what works for ME. Please be sure to speak with a trusted physician ...

By: Sheila Kalkbrenner

Here is the original post:
Living With Arachnoiditis: Coping with Obliterated Cervical Lordosis - Video

Recommendation and review posted by sam

2 Introduction to the Global Alliance for Regenerative Medicine, "GARM", Roatan, Honduras
Glenn Terry M. D. is the founder of GARM, a global alliance of international researchers and physicians who have teamed with Honduras specialists and experts...

By: Global Alliance for Regenerative Medicine, Roatan, Honduras

Original post:
2 Introduction to the Global Alliance for Regenerative Medicine, "GARM", Roatan, Honduras - Video

Recommendation and review posted by sam

4 Jose Samara, M D , CEO Cemesa Hospital System
Jose Samara M. D. is the Founder and Chief executive for Cemesa, the hospital system on Roatan, Honduras. Dr Samara is the Chairman for the Global Alliance f...

By: Global Alliance for Regenerative Medicine, Roatan, Honduras

Read more:
4 Jose Samara, M D , CEO Cemesa Hospital System - Video

Recommendation and review posted by sam

11 WebOps 1
This company provides a service whereby stem cell biopsies can be stored fresh from the operating table in a specially deigned canister which maintains an in...

By: Global Alliance for Regenerative Medicine, Roatan, Honduras

The rest is here:
11 WebOps 1 - Video

Recommendation and review posted by sam

By Maggie Fox

One of the worlds leading stem cell experts has suggested withdrawing a study that made global headlines last January, saying he has questions about some of the images and data in it.

The Japanese team, led by Teruhiko Wakayama, reported that they had created powerful stem cells by doing little more than soaking ordinary cells in an acid solution.

The report, published in the journal Nature, impressed other stem cell researchers and opened the possibility of an easy approach to regenerative medicine. But Japanese television quotes Wakayama as saying he wants to take a closer look.

"When conducting the experiment, I believed it was absolutely right, Reuters news agency quotes Wakayama as telling the television station NHK.

"But now that many mistakes have emerged, I think it is best to withdraw the research paper once and, using correct data and correct pictures, to prove once again the paper is right," he said.

"If it turns out to be wrong, we would need to make it clear why a thing like this happened."

But Charles Vacanti of Harvard Medical School and Brigham and Women's Hospital in Boston, who helped work on the study, said he disagreed. "Some mistakes were made, but they don't affect the conclusions," the Wall Street Journal quoted him as saying.

"Based on the information I have, I see no reason why these papers should be retracted."

Stem cell researchers may be more sensitive than other scientists. In 2006, Seoul National University fired Hwang Woo-Suk after the journal Science retracted two papers he wrote claiming to have cloned human embryos and extracted stem cells from them.

Read the original:
Stem Cell Researcher Suggests Recalling His Own Study

Recommendation and review posted by simmons

Seven months after a bill to create a regional stem cell therapy hub at The University of Kansas Medical Center took effect, two doctors from the center say it is enrolling patients in clinical trials and they are beginning their work.

David Prentice and Buddhadeb Dawn expressed excitement Monday about what the Midwest Stem Cell Therapy Center has been able to accomplish in a short time and what possibilities it holds for the future.

"Kansas can be the leader in providing adult stem cell treatments and information to physicians and patients around the world," Dawn said.

Prentice said the center, which limits itself to research on adult stem cells, will foster "ethical, noncontroversial" treatments for patients with multiple sclerosis, spinal cord injuries, heart damage, stroke and juvenile diabetes.

At the same time he said it will serve to educate schoolchildren on the promise of adult stem cells and act as a "hub" for regional research.

Potentially, physicians from across the region could be sending samples," Prentice told the Senate Ways and Means Committee that approved millions in start-up funds for the center last year.

Sen. Jeff Melcher, R-Leawood, said he was heartened by news of the center beginning work, but somewhat concerned about it monetizing that work.

He noted that the 15 members of the center's advisory board are academics and legislators, with no one from the business community.

I see kind of a void in that I dont see the people that it would take to product-ize this," Melcher said. "The sales and marketing expertise, the product development.

Dawn said the medical center has some in-house experts who can help with that and that it also will be working with specific companies in some of its clinical trials.

Link:
Stem cell center starting trials

Recommendation and review posted by simmons

Topeka Eight months after the establishment of the Midwest Stem Cell Therapy Center at Kansas University Medical Center, the center is conducting clinical trials and advancing treatments for numerous diseases, KU officials said Monday.

"We are very excited about the work that is going on," said Dr. Doug Girod, executive vice chancellor of the KU Medical Center.

Dr. Buddhadeb Dawn, the center's director, detailed clinical trials that are under way and several in the planning stages to the Senate Ways and Means Committee.

"These trials will help local patients to get access to stem cell therapy," Dawn said. "Kansas can be a leader in providing stem cell treatments."

Created last year by the Legislature and Gov. Sam Brownback, the center will work on adult stem cell, cord blood and related stem cell research, providing therapies to patients and serving as a clearinghouse for physicians on cutting-edge treatments.

The center is prohibited from using embryonic stem cells or cells taken from aborted fetal tissue. Abortion opponents oppose human embryonic stem cell research because it involves the destruction of the embryo.

David Prentice, senior fellow for life sciences of the Family Research Council, said the center was unique in the country.

Prentice, who was involved in the development of the center and is on the center's advisory board as a representative of the scientific community, said, "I do want to reemphasize the focus on the center is patient-centered," while also working on education, clinical trials and research.

The FRC describes itself as a Christian organization promoting the traditional family unit and the Judeo-Christian value system. Its critics say it spreads anti-gay propaganda.

State Sen. Jeff Melcher, R-Overland Park, said the research sounded exciting but that he was concerned that the advisory board had no business people on it to secure private and business funding.

See the article here:
Stem Cell Center advancing treatments, officials say

Recommendation and review posted by simmons

Freeport, The Bahamas (PRWEB) March 10, 2014

Matt Feshbach, CEO of Okyanos Heart Institute whose mission it is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy has announced the appointment of Okyanos senior vice president of marketing, Erika Rosenthal, to the International Stem Cell Society (STEMSO) Advisory Board. She will advise the trade organization in a communications capacity to benefit the membership and the mission.

STEMSO is a member-based, international, non-profit 501(c) 6 trade association which promotes the interests of organizational members of the global, adult stem cell healthcare community. STEMSO provides information, education, resources, advocacy and public awareness for the advancement of adult stem cell research and therapy. The organization recently hosted a global regenerative medicine conference in Freeport, The Bahamas, entitled, Bridging the Gap: Research to Point of Care which brought together experts in adult stem cell therapy and regulations to discuss commercialization of therapies for chronic disease in a safe, ethical, and compliant manner.

STEMSO is an important organization to the field of stem cell therapy and research, said Feshbach. Communications and healthcare are both fields in which Erika excels, and so I am pleased to see her lend her expertise for an important cause. I look forward to the Okyanos Heart Institute executive team continuing with such efforts for the greater good of medicine.

Rosenthal was a 2008 recipient of the National Association of Women Business Owners Business Woman of the Year award, and was recognized in Business Leader Magazine as a Woman Extraordinaire, for her business accomplishments and contributions to the non-profit community. She is a former faculty member of the University of California where she taught Marketing and Hospitality Management.

It is indeed an honor to work with STEMSO to advance their cause to help advance adult stem cell research and therapy worldwide, and to bring together leading researchers, physicians, regulators and scientists to set standards for ethical and responsible delivery of therapies as they become available to the public worldwide, said Rosenthal. It is an exciting time in medicine, and STEMSO is greatly needed to bring collaboration and guidance between this impressive member group of thought leaders.

STEMSO is pleased to have Erika Rosenthal participate on STEMSOs Advisory Board, said Douglas Hammond, president of STEMSO. Non-profit trade associations are only as strong as their member participation and leadership allows. If other members or prospective organizational members were to support STEMSO as Okyanos Heart Institute and Erika Rosenthal, there would be no limit to STEMSOs impact in the Regenerative Medicine Industry.

About Okyanos Heart Institute: (Oh key AH nos) Based in Freeport, The Bahamas, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive procedure, can stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart, which supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos, the Greek god of rivers, symbolizes restoration of blood flow.

END

Read the rest here:
Okyanos CEO Matt Feshbach Announces Appointment of Institutes Marketing Executive Erika Rosenthal to International ...

Recommendation and review posted by Bethany Smith

Mar 09, 2014 This photo shows Dr. Sean Morrison, Director of the Children's Research Institute and senior author of the study, right, and Dr. Robert A.J. Signer, a postdoctoral research fellow and the study's first author. Credit: University of Texas Southwestern Medical Center

For the first time, researchers have shown that an essential biological process known as protein synthesis can be studied in adult stem cells something scientists have long struggled to accomplish. The groundbreaking findings from the Children's Medical Center Research Institute at UT Southwestern (CRI) also demonstrate that the precise amount of protein produced by blood-forming stem cells is crucial to their function.

The discovery, published online today in Nature, measures protein production, a process known as translation, and shows that protein synthesis is not only fundamental to how stem cells are regulated, but also is critical to their regenerative potential.

"We unveiled new areas of cellular biology that no one has seen before," said Dr. Sean Morrison, Director of the Children's Research Institute, Professor of Pediatrics, and the Mary McDermott Cook Chair in Pediatric Genetics at UT Southwestern Medical Center. "No one has ever studied protein synthesis in somatic stem cells. This finding not only tells us something new about stem cell regulation, but opens up the ability to study differences in protein synthesis between many kinds of cells in the body. We believe there is an undiscovered world of biology that allows different kinds of cells to synthesize protein at different rates and in different ways, and that those differences are important for cellular survival."

Dr. Adrian Salic's laboratory at Harvard Medical School chemically modified the antibiotic puromycin in a way that made it possible to visualize and quantify the amount of protein synthesized by individual cells within the body. Dr. Robert A.J. Signer, a postdoctoral research fellow in Dr. Morrison's laboratory and first author of the study, realized that this reagent could be adapted to measure new protein synthesis by stem cells and other cells in the blood-forming system.

What they came across was astonishing, Dr. Morrison said. The findings suggested that different types of blood cells produce vastly different amounts of protein per hour, and stem cells in particular synthesize much less protein than any other blood-forming cells.

"This result suggests that blood-forming stem cells require a lower rate of protein synthesis as compared to other blood-forming cells," said Dr. Morrison, the paper's senior author.

Researchers applied the findings to a mouse model with a genetic mutation in a component of the ribosome the machinery that makes proteins and the rate of protein production was reduced in stem cells by 30 percent. The scientists also increased the rate of protein synthesis by deleting the tumor suppressor gene Pten in blood-forming stem cells. In both instances, stem cell function was noticeably impaired.

Together, these observations demonstrate that blood-forming stem cells require a highly regulated rate of protein synthesis, such that increases or decreases in that rate impair stem cell function.

"Amazingly, when the ribosomal mutant mice and the Pten mutant mice were bred together, stem cell function returned to normal, and we greatly delayed, and in some instances entirely blocked, the development of leukemia," Dr. Morrison said. "All of this happened because protein production in stem cells was returned to normal. It was as if two wrongs made a right."

Read this article:
Stem cell study opens door to undiscovered world of biology

Recommendation and review posted by Bethany Smith

San Diego, CA (PRWEB) March 10, 2014

Histogen Aesthetics, a subsidiary of regenerative medicine company Histogen, Inc. focused on skin care and cosmeceuticals, announced today that the Company has acquired the CellCeuticals Biomedical Skin Treatments line of skincare products.

Histogen Aesthetics will continue sales of the eleven existing CellCeuticals Biomedical Skin Treatments skincare products, while bringing new innovation to the line through the addition of a unique regenerative medicine technology, working to improve skin aging at a cellular level.

We have long admired the science, clinical data and elegant formulas behind the CellCeuticals line, and see it as an ideal fit for our recently revitalized aesthetics subsidiary, said Dr. Gail K. Naughton, CEO and Chairman of Histogen, Inc. We are very excited to begin infusing unique cell-signaling factors into the CellCeuticals regimen, to truly transform skin one cell at a time.

Dr. Naughton has spent more than 30 years in tissue engineering and regenerative medicine, and holds over 100 patents in the field. She founded Histogen in 2007, focused on developing therapies that work to stimulate the stem cells in the body to regenerate tissues and organs. Through this work, she has also seen how different compositions of human proteins can have cosmetic benefits, particularly in anti-aging and rejuvenation.

I am pleased that the CellCeuticals Biomedical Skin Treatments will evolve, and see Histogen Aesthetics as an excellent home for this innovative product line, said Paul Scott Premo, co-founder of CellCeuticals Skin Care, Inc. I believe the addition of this regenerative medicine technology will be the opportunity to introduce a new generation of products that are the vanguard of regenerative skin care.

The CellCeuticals system is made up of eleven distinctive products including the Extremely Gentle Skin Cleanser, CellGenesis Regenerative Skin Treatment, and PhotoDefense Color Radiance SPF55+ with proprietary and patented PhotoPlex technology. The line is currently available at retailers including QVC.com, Dermstore.com, and Nordstrom.com, as well as http://www.cellceuticalskincare.com.

About Histogen Aesthetics Histogen Aesthetics LLC, formed in 2008 as a subsidiary of Histogen, Inc., focuses on the development of innovative skin care products utilizing regenerative medicine technology. Histogen Aesthetics technology is based on the expertise of founder Dr. Gail K. Naughton, in which fibroblasts are grown under unique conditions, producing a complex of naturally-secreted proteins and synergistic bio-products known to stimulate skin cells to regenerate and rejuvenate tissues. In 2014, Histogen Aesthetics acquired CellCeuticals Biomedical Skin Treatments, a line of scientifically-proven products that reactivate cells to help aging skin perform and look healthier and younger. For more information, visit http://www.cellceuticalskincare.com.

About Histogen Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's lead product, Hair Stimulating Complex (HSC) has shown success in two Company-sponsored clinical trials as an injectable treatment for alopecia. In addition, the human multipotent cell conditioned media produced through Histogen's process is also being researched for oncology applications, and in orthopedics through joint venture PUR Biologics, LLC. For more information, please visit http://www.histogen.com.

Go here to read the rest:
Histogen Aesthetics Acquires CellCeuticals Biomedical Skin Treatments

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

9-Mar-2014

Contact: Henry Rummins h.rummins@ucl.ac.uk 44-207-679-9063 University College London

Japanese pharmaceutical company Takeda will work with University College London (UCL) to drive research into tackling muscle disorders, in particular muscular dystrophy.

The research which is being conducted by the research group of Dr Francesco Saverio Tedesco is being supported through funding of $250,000 from the company's New Frontier Sciences group. Takeda's NFS aims to support innovative, cutting-edge research which could eventually lead to drug discovery and development.

Dr Tedesco's team will focus on the study of muscular regeneration and the potential for stem cell therapies to treat muscular dystrophy, in particular induced pluripotent (iPS) stem cells.

The team is also investigating the potential for treating muscular dystrophy through developing novel gene and cell therapy strategies using artificial human chromosomes and novel biomaterials.

Using this approach, Dr Tedesco hopes to overcome a number of current limitations to developing effective treatments for muscular dystrophies. It is hoped that through the use of these modified stem cells, large quantities of progenitor cells could be produced to be transplanted into a patient's muscle following genetic correction or to be used for drug development platforms.

Importantly, the team will attempt to produce these cells which can be applied more easily in a clinical context, in order to reduce the hurdles that might limit their possible future use in clinical studies.

Through previous work using a mouse model of Duchenne muscular dystrophy, the team has already demonstrated the potential of pre-clinical gene replacement therapy using an artificial human chromosome.

Read more here:
Takeda and UCL to work together to tackle muscle disorders

Recommendation and review posted by Bethany Smith

Stem cell transplant was viable and effective in halting or reversing degenerative disc disease of the spine, a meta-analysis of animal studies showed, in a development expected to open up research in humans. Recent developments in stem cell research have made it possible to assess its effect on intervertebral disc (IVD) height, Mayo Clinic researchers reported in a scientific poster today at the 30th Annual Meeting of the American Academy of Pain Medicine.

"This landmark study draws the conclusion in pre-clinical animal studies that stem cell therapy for disc degenerative disease might be a potentially effective treatment for the very common condition that affects people's quality of life and productivity," said the senior author, Wenchun Qu, MD, PhD, of the Mayo Clinic in Rochester, Minn.

Dr. Qu said not only did disc height increase, but stem cell transplant also increased disc water content and improved appropriate gene expression. "These exciting developments place us in a position to prepare for translation of stem cell therapy for degenerative disc disease into clinical trials," he said.

The increase in disc height was due to restoration in the transplant group of the nucleus pulposus structure, which refers to the jelly-like substance in the disc, and an increased amount of water content, which is critical for the appropriate function of the disc as a cushion for the spinal column, the researchers concluded.

The researchers performed a literature search of MEDLINE, EMBASE and PsycINFO databases and also manually searched reference lists for original, randomized, controlled trials on animals that examined the association between IVD stem cell transplant and the change of disc height. Six studies met inclusion criteria. Differences between the studies necessitated the use of random-effects models to pool estimates of effect.

What they found was an over 23.6% increase in the disc height index in the transplant group compared with the placebo group (95% confidence interval [CI], 19.7-23.5; p<0.001). None of the 6 studies showed a decrease of the disc height index in the transplant group. Increases in the disc height index were statistically significant in all individual studies.

The authors commented that it is time to turn attention to the much-needed work of determining the safety, feasibility, efficacy of IVD stem cell transplant for humans.

"A hallmark of IVD degenerative disease is its poor self-repair capacity secondary to the loss of IVD cells. However, current available treatments fail to address the loss of cells and cellular functions. In fact, many invasive treatments further damage the disc, causing further degeneration in the diseased level or adjacent levels," said the lead study author Jason Dauffenbach, DO. "The goal of tissue engineering using stem cells is to restore the normal function and motion of the diseased human spine."

Story Source:

The above story is based on materials provided by American Academy of Pain Medicine (AAPM). Note: Materials may be edited for content and length.

Continued here:
Stem cell transplant shows 'landmark' promise for treatment of degenerative disc disease

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

9-Mar-2014

Contact: Henry French henry.french@icr.ac.uk 020-715-35312 Institute of Cancer Research

Mutations in a gene associated with leukaemia cause a newly described condition that affects growth and intellectual development in children, new research reports.

A study led by scientists at The Institute of Cancer Research, London, identified mutations in the DNA methyltransferase gene, DNMT3A, in 13 children.

All the children were taller than usual for their age, shared similar facial features and had intellectual disabilities. The mutations were not present in their parents, nor in 1,000 controls from the UK population.

The new condition has been called 'DNMT3A overgrowth syndrome'.

The research is published today (Sunday) in the journal Nature Genetics and is a part of the Childhood Overgrowth Study, which is funded by the Wellcome Trust, and aims to identify causes of developmental disorders that include increased growth in childhood. The DNMT3A gene is crucial for development because it adds the 'methylation' marks to DNA that determine where and when genes are active.

Intriguingly, DNMT3A mutations are already known to occur in certain types of leukaemia. The mutations that occur in leukaemia are different from those in DNMT3A overgrowth syndrome and there is no evidence that children with DNMT3A mutations are at increased risk of cancer.

Researchers at The Institute of Cancer Research (ICR), with colleagues at St George's, University of London, The Royal Marsden NHS Foundation Trust, and genetics centres across Europe and the US, identified the mutations after analysing the genomes of 152 children with overgrowth disorders and their parents.

More:
Mutations in leukemia gene linked to new childhood growth disorder

Recommendation and review posted by Bethany Smith

London (PRWEB UK) 10 March 2014

Research has found that the stress gene has been linked to a higher risk of dying from a heart attack or heart disease. But, fear not, a group of doctors from Duke University of Medicine have now found that early identification of the gene and treatment of people at higher risk may reduce the chances of having a fatal heart attack.

The team also found that patients who had the genetic stress gene had a 38% increased chance of having a heart attack or suffering from fatal heart disease, compared to those without, even after taking into account factors such as age, obesity and smoking.

Superintendent Pharmacist at ChemistDirect, Omar El-Gohary, said: The so called stress gene is called 5HTR2C. This gene is involved in the regulation of a stress hormone called Cortisol. A person with this stress gene produces almost twice as much Cortisol when stressed, leading to the softening of the arteries and eventually leading to clots and bursting.

The research suggests that stress management techniques and drug therapies could reduce deaths and disabilities, and this is the first positive step towards finding genetic variants that identify people at higher risk of cardiovascular disease.

El-Gohary said: Stress management can also include eating healthily and doing regular exercise. Anger and stress play instrumental roles in causing heart attacks, so if you are prone to this, you should try to manage them through coping strategies or therapy.

In the study, about one in 10 men and 3% of women in the group of 6,000 heart patients had the genetic change associated with handling emotional stress badly. Professors at the British Heart Foundation said that the results provided further evidence that stress may directly increase the risk of heart disease. (http://bbc.in/1bTfU1c)

The reason why the genetic change increases the risk of heart attack is relatively unknown. The extensive studies being done in America and by the British Heart Foundation continue to prove that a positive lifestyle change can help cope with stress and may be an easy way to reduce risk. (http://bit.ly/1cHPYYs)

El-Gohary advises that if a feeling of anxiousness and stress continues for a prolonged period of time, to make an appointment with a doctor.

Read more:
New research reveals the benefits of identifying the stress gene Chemist Direct discovers

Recommendation and review posted by Bethany Smith

Current ratings for: Leukemia gene mutation linked to new childhood growth disorder

Public / Patient:

0 0 ratings

Health Professionals:

0 0 ratings

New research led by the Institute of Cancer Research in the UK has discovered that a gene mutation associated with leukemia may be the cause of a newly described condition that affects the growth and intellectual development of children.

This is according to a study recently published in the journal Nature Genetics.

To reach their findings, the research team analyzed the genomes of 152 children with overgrowth disorders and their parents, alongside 1,000 controls from the UK population.

Overgrowth disorders are a group of genetic disorders that cause an abnormal increase in body size, as well as intellectual disability and facial dysmorphism. Such disorders already described include Beckwith-Wiedemann syndrome and Weaver syndrome.

The researchers discovered that 13 of the children had mutations in the DNA methyltransferase gene - DNMT3A. All children with these mutations were taller than usual for their age, had intellectual disabilities and shared similar facial features.

Follow this link:
Leukemia gene mutation linked to new childhood growth disorder

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

9-Mar-2014

Contact: Lisa Horton l.horton@uea.ac.uk 44-016-035-92764 University of East Anglia

Farmed salmon show full reproductive potential to invade wild gene pools and should be sterilised - according to new research from the University of East Anglia (UEA).

Findings published today reveal that, while farmed salmon are genetically different to their wild counterparts, they are just as fertile. This is important information because millions of farmed salmon escape into the wild posing threats to wild gene pools.

Lead Researcher Prof Matt Gage from UEA's school of Biological Sciences said: "Around 95 per cent of all salmon in existence are farmed, and domestication has made them very different to wild populations, each of which is locally adapted to its own river system.

"Farmed salmon grow very fast, are aggressive, and not as clever as wild salmon when it comes to dealing with predators. These domestic traits are good for producing fish for the table, but not for the stability of wild populations.

"The problem is that farmed salmon can escape each year in their millions, getting into wild spawning populations, where they can then reproduce and erode wild gene pools, introducing these negative traits.

"We know that recently-escaped farmed salmon are inferior to wild fish in reproduction, but we do not have detailed information on sperm and egg performance, which could have been affected by domestication. Our work shows that farm fish are as potent at the gamete level as wild fish, and if farm escapes can revive their spawning behaviour by a period in the wild, clearly pose a significant threat of hybridisation with wild populations."

Researchers used a range of in vitro fertilization tests in conditions that mimicked spawning in the natural environment, including tests of sperm competitiveness and egg compatibility. All tests on sperm and egg form and function showed that farmed salmon are as fertile as wild salmon identifying a clear threat of farmed salmon reproducing with wild fish.

Continued here:
Farm salmon pose clear reproductive threat to wild gene pools

Recommendation and review posted by Bethany Smith

How to say genetic engineering in Italian

By: How to say in Italian ?

Read the original:
How to say genetic engineering in Italian - Video

Recommendation and review posted by Bethany Smith

Kerala cannot afford to overlook the potential of Genetically Modified (GM) crops to emerge as a substitute for toxic chemicals used against plant parasites in polyhouse cultivation, Swapan K. Dutta, Deputy Director General (Crop Sciences), Indian Council for Agricultural Research (ICAR) has said.

Talking to The Hindu on the sidelines of the National Biennial Group Meeting of the All India Coordinated Research Project on Nematode pests here earlier this week, he said states like Kerala that were increasingly turning to protected cultivation could no longer ignore the benefits of genetic engineering for pest and disease control.

Dr. Dutta said biotechnology and genetic engineering would assume a greater role in the battle against pathogens and plant diseases that caused crop loss. The controlled conditions that help to optimise crop production inside a polyhouse are conducive for pests as well, forcing farmers to use toxic chemicals for control. Through genetic engineering, the plant itself develops protection against pathogens. That way you avoid toxic chemicals. States like Kerala will soon have to pay attention to GM technology.

Highlighting the potential of plant genetic resources, he said, In nature, plants continuously try to defend themselves against hundreds of thousands of pathogenic bacteria and nematodes. If scientists can understand the genes that plants activate against pathogens or diseases, it will be a million dollar discovery with potential impact on plant as well as human health. Understanding the resistance mechanism of the gene could provide a breakthrough in disease control.

Terming Keralas move to switch over to organic farming as a political gimmick, Dr. Dutta said it had no meaning. It is not possible for a whole State to make the switch to organic farming. Our experiments show that organic farming will not give sustainable production and high productivity.

Observing that farmers in Kerala, like their counterparts elsewhere in the country, used subsidized fertilizers and other chemicals, Dr. Dutta noted that there were some niche areas like speciality and high-value fruits and vegetables that could be kept organic. Organic farming helps in increasing soil fertility. But to keep production and productivity high, you need to have other fertilizers.

Dr. Dutta said plant-parasitic soil nematodes, a microscopic variety of worms, constituted a major threat for protected cultivation of fruits, vegetables and flowers. Surveillance, monitoring and pest management assume more importance in protected cultivation.

Originally posted here:
ICAR stresses GM technology for Kerala

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

10-Mar-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, March 10, 2014Nearly $7 billion is spent each year in the U.S. on diagnostic testing of the estimated three million people with symptoms of obstructive coronary artery disease (CAD). A new blood test that detects specific genes activated in individuals with obstructive CAD could exclude the diagnosis without the need for imaging studies or more invasive tests, reducing health care costs, as described in an article in Population Health Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Population Health Management website at http://www.liebertpub.com/pop.

Louis Hochheiser (St. John's Medical Center, Jackson, WY), Jessie Juusola and Mark Monane (CardioDx, Palo Alto, CA), and Joseph Ladapo (New York University School of Medicine, NY), use a decision analysis model to compare the cost-effectiveness of "usual care" for obstructive CAD diagnosis with a strategy that includes "gene expression score (GES)-directed care." They present the results and potential value of this new diagnostic approach in the article "Economic Utility of a Blood-Based Genomic Test for the Assessment of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease".

"Work like this is vital to our understanding as we move from a world of volume to value," says Editor-in-Chief David B. Nash, MD, MBA, Dean and Dr. Raymond C. and Doris N. Grandon Professor, Jefferson School of Population Health, Philadelphia, PA.

###

About the Journal

Population Health Management is an authoritative peer-reviewed journal published bimonthly in print and online that reflects the expanding scope of health care management and quality. The Journal delivers a comprehensive, integrated approach to the field of population health and provides information designed to improve the systems and policies that affect health care quality, access, and outcomes. Comprised of peer-reviewed original research papers, clinical research, and case studies, the content encompasses a broad range of chronic diseases (such as cardiovascular disease, cancer, chronic pain, diabetes, depression, and obesity) in addition to focusing on various aspects of prevention and wellness. Tables of content and a sample issue may be viewed on the Population Health Management website at http://www.liebertpub.com/pop. Population Health Management is the official journal of the Population Health Alliance.

About the Publisher

View post:
Genomic test to rule out obstructive CAD may reduce need for more invasive diagnostics

Recommendation and review posted by Bethany Smith

Dear EarthTalk: Should those of us who care about our health and the planet be concerned about the new trend in genetic engineering called synthetic biology? Chrissie Wilkins, Bern, N.C.

Synthetic biology (or synbio) refers to the design and fabrication of novel biological parts, devices and systems that do not otherwise occur in nature. Many see it as an extreme version of genetic engineering (GE). But unlike GE, whereby genetic information with certain desirable traits is inserted from one organism into another, synbio uses computers and chemicals to create entirely new organisms.

Proponents of synbio, which include familiar players such as Cargill, BP, Chevron and Du Pont, tout its potential benefits. According to the Synthetic Biology Engineering Research Center (SYNBERC), a consortium of leading U.S. researchers in the field, some promising applications of synthetic biology include alternatives to rubber for tires, tumor-seeking microbes for treating cancer, and photosynthetic energy systems. Other potential applications include using synbio to detect and remove environmental contaminants, monitor and respond to disease and develop new drugs and vaccines.

While these and other applications may not be widely available for years, synthetic biology is already in use for creating food additives that will start to show up in products on grocery shelves later this year. Switzerland-based Evolva is using synthetic biology techniques to produce alternatives to resveratrol, stevia, saffron and vanilla. The companys synthetic vanillin is slated to go into many foods as a cheaper and limitless version of real vanilla flavor. But many health advocates are outraged that such a product will be available to consumers without more research into potential dangers and without any warnings or labeling to let consumers know they are eating organisms designed and brought to life in a lab.

This is the first major use of a synbio ingredient in food, and dozens of other flavors and food additives are in the pipeline, so synbio vanilla could set a dangerous precedent for synthetic genetically engineered ingredients to sneak into our food supply and be labeled as natural, reports Friends of the Earth (FoE), a leading environmental group. Synthetic biology vanillin poses several human health, environmental and economic concerns for consumers, food companies and other stakeholders.

For example, FoE worries that synbio vanilla (and eventually other synthetic biology additives) could exacerbate rainforest destruction while harming sustainable farmers and poor communities around the world. Synbio vanillacould displace the demand for the natural vanilla market, reports FoE. Without the natural vanilla market adding economic value to the rainforest in these regions, these last standing rainforests will not be protected from competing agricultural markets such as soy, palm oil and sugar. Critics of synbio also worry that releasing synthetic life into the environment, whether done intentionally or accidentally, could have adverse effects on our ecosystems.

Despite these risks, could the rewards of embracing synthetic biology be great? Could it help us deal with some of the tough issues of climate change, pollution and world hunger? Given that the genie is already out of the bottle, perhaps only time will tell.

EarthTalk is written and edited by Roddy Scheer and Doug Moss and is a registered trademark of E-The Environmental Magazine http://www.emagazine.com. Send questions to: earthtalk@emagazine.com.

Read the original post:
Should we be concerned with synthetic biology?

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

10-Mar-2014

Contact: David Ruth david@rice.edu 713-348-6327 Rice University

In a significant advance for the growing field of synthetic biology, Rice University bioengineers have created a toolkit of genes and hardware that uses colored lights and engineered bacteria to bring both mathematical predictability and cut-and-paste simplicity to the world of genetic circuit design.

"Life is controlled by DNA-based circuits, and these are similar to the circuits found in electronic devices like smartphones and computers," said Rice bioengineer Jeffrey Tabor, the lead researcher on the project. "A major difference is that electrical engineers measure the signals flowing into and out of electronic circuits as voltage, whereas bioengineers measure genetic circuit signals as genes turning on and off."

In a new paper appearing online today in the journal Nature Methods, Tabor and colleagues, including graduate student and lead author Evan Olson, describe a new, ultra high-precision method for creating and measuring gene expression signals in bacteria by combining light-sensing proteins from photosynthetic algae with a simple array of red and green LED lights and standard fluorescent reporter genes. By varying the timing and intensity of the lights, the researchers were able to control exactly when and how much different genes were expressed.

"Light provides us a powerful new method for reliably measuring genetic circuit activity," said Tabor, an assistant professor of bioengineering who also teaches in Rice's Ph.D. program in systems, synthetic and physical biology. "Our work was inspired by the methods that are used to study electronic circuits. Electrical engineers have tools like oscilloscopes and function generators that allow them to measure how voltage signals flow through electrical circuits. Those measurements are essential for making multiple circuits work together properly, so that more complex devices can be built. We have used our light-based tools as a biological function generator and oscilloscope in order to similarly analyze genetic circuits."

Electronic circuits -- like those in computers, smartphones and other devices -- are made up of components like transistors, capacitors and diodes that are connected with wires. As information -- in the form of voltage -- flows through the circuit, the components act upon it. By putting the correct components in the correct order, engineers can build circuits that perform computations and carry out complex information processing.

Genetic circuits also process information. Their components are segments of DNA that control whether or not a gene is expressed. Gene expression is the process in which DNA is read and converted to produce a product -- such as a protein -- that serves a particular purpose in the cell. If a gene is not "expressed," it is turned off, and its product is not produced. The bacteria used in Tabor's study have about 4,000 genes, while humans have about 20,000. The processes of life are coordinated by different combinations and timings of genes turning on and off.

Each component of a genetic circuit acts on the input it receives -- which may be one or more gene-expression products from other components -- and produces its own gene-expression product as an output. By linking the right genetic components together, synthetic biologists like Tabor and his students construct genetic circuits that program cells to carry out complex functions, such as counting, having memory, growing into tissues, or diagnosing the signatures of disease in the body.

Here is the original post:
Rice synthetic biologists shine light on genetic circuit analysis

Recommendation and review posted by Bethany Smith

March 10, 2014

Rebekah Eliason for redOrbit.com Your Universe Online

A study from Northwestern Medicine has led to a new theory regarding the development and cause of endometriosis. The chronically painful disease, which affects 1 in 10 women, has been linked to two previously unstudied genes.

This innovative research regarding endometriosis suggests that an integral part of the disease and its progression is epigenetic modification, which is a process that will either enhance or disrupt the reading of DNA.

Matthew Dyson, research assistant professor of obstetrics and gynecology at Northwestern University Feinberg School of Medicine, along with Serdar Bulun, MD, chair of obstetrics and gynecology at Feinberg and Northwestern Memorial Hospital, were able to recognize a novel role for a family of key gene regulators found in the uterus.

Until now, the scientific community was looking for a genetic mutation to explain endometriosis, said Bulun, a member of the Center for Genetic Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. This is the first conclusive demonstration that the disease develops as a result of alterations in the epigenetic landscape and not from classical genetic mutations.

Heather C. Guidone, Surgical Program Director at The Center for Endometriosis Care explains that, Endometriosis results when tissue similar to that which lines the uterus grows in other areas of the body. The persistent survival of these cells results in chronic pelvic pain, organ dysfunction, infertility and more. Although the cause of the disease has remained unknown on a cellular level, there have been several different models established to explain its development.

Since endometriosis is only found in menstruating primates, it is likely that the unique evolution of uterine development and menstruation are connected with the disease. Retrograde menstruation, the movement of cells up the fallopian tubes and into the pelvis, has long been considered by scientists as a probable cause of endometriosis. Since most women experience retrograde menstruation at some point, this model fails to explain why only ten percent of women develop the disease. In addition, this theory is insufficient at explaining instances where endometriosis arises independent of menstruation.

Bulun and Dyson theorize that there is an epigenetic switch that allows the expression of the genetic receptor GATA6 instead of GATA2. This results in progesterone resistance leading to development of the disease.

We believe an overwhelming number of these altered cells reach the lining of the abdominal cavity, survive and grow, Bulun said. These findings could someday lead to the first noninvasive test for endometriosis.

Read the rest here:
Endometriosis Cause And Development Linked To Unstudied Genes

Recommendation and review posted by Bethany Smith

Technical Beast :: Advanced Genetics :: Modded Minecraft 1.6.4
We take a look at Advanced Genetics. My Channel: https://www.youtube.com/user/Rabenschild My Twitter: https://twitter.com/Rabenschild RedstoneNightmare: http...

By: Rabenschild

See the rest here:
Technical Beast :: Advanced Genetics :: Modded Minecraft 1.6.4 - Video

Recommendation and review posted by Bethany Smith

Attack of the B-Team 08 - "Applied Genetics" 😀
Hey guys, In this episode we Work on "ADVANCED GENETICS" Skylar also tries out self commentary!

By: Xian Games

Continued here:
Attack of the B-Team 08 - "Applied Genetics" 😀 - Video

Recommendation and review posted by Bethany Smith